Standard of Care And The Internet Of Medical Things
Back to Insights Your Content Goes Here LEARN MORE
TEDs’ Driving Change in U.S. Health Care
Back to Insights Your Content Goes Here LEARN MORE
4 Ways Precision Medicine Impacts Cancer Treatment
Back to Insights Your Content Goes Here LEARN MORE
Machine Learning In Clinical Trials: What Will The Future Hold (And What’s Holding Us Back)?
Back to Insights Your Content Goes Here LEARN MORE
FDA Unveils Final Interchangeability Guidance for Biosimilars
The FDA has finally released its guidance on biosimilar interchangeability. Radar on Specialty Pharmacy speaks with Ryan Cox, Precision for Value Vice President, Access Experience team on how the new guidelines reduce administrative hurdles and duplicative clinical trials. However, he notes that reimbursement issues may discourage uptake.
Show Me The Data: Why Payers Need to See RWE Used in New Indication Approvals
Back to Insights Your Content Goes Here LEARN MORE
CBO says Proposed Rule to Kill Rebates Will Increase Spending by $177 Billion
Increasing patient savings and reducing government spending are laudable goals. But neither the CBO nor Precision experts Jeremy Schafer, Jacki Chou, and Harry G. Schiavi believe the proposed HHS rule will work. In this Spotlight on Market Access article, they join other industry leaders in discussing the potential repercussions of the rule.
The Health Care Ecosystem and Social Determinants of Health: Surveys Suggest the State is Set for Novel Combinations
Back to Insights Your Content Goes Here LEARN MORE
CBO says Proposed Rebate Rule Will Cost Government $177B
HHS wants to eliminate drug rebates in Medicare Part D and Medicaid managed care. But the CBO projects the resulting higher premiums will cost the government dearly. In an AIS Health, Radar on Specialty Pharmacy article, Jeremy Schafer, Precision for Value Senior Vice President, Access Experience, weighs in on the potential impact of the rule, and what that means for its future.
